Annals of Hematology

, Volume 86, Issue 6, pp 435–442

High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival

  • Min Kyoung Kim
  • Shin Kim
  • Sung Sook Lee
  • Sun Jin Sym
  • Dae Ho Lee
  • Seongsoo Jang
  • Chan Jeong Park
  • Hyun Sook Chi
  • Jooryung Huh
  • Cheolwon Suh
Original Article


Although the role of high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in the treatment of aggressive lymphoma has been established in several large prospective studies, its effectiveness in patients with peripheral T cell lymphoma (PTCL) has not been defined. We aimed to evaluate the efficacy of HDT and ASCT and prognostic factors for survival in patients with PTCL. We retrospectively analyzed the results of 40 PTCL patients treated with HDT and ASCT at Asan Medical Center between January 1995 and December 2005. Twenty patients had PTCL-U (peripheral T cell lymphoma, unspecified), 10 had extranodal natural killer/T cell lymphoma, 5 had anaplastic large cell lymphoma, 3 had angioimmunoblastic T cell lymphoma, 1 had hepatosplenic γσ T cell lymphoma, and 1 had disseminated mycosis fungoides. Disease status at transplant was complete response (CR)1 in 3 patients, CR2 or greater in 8, partial remission in 25, and refractory in 4. At a median follow-up of 16 months (range, 5 to 135 months) for surviving patients, the median overall survival (OS) was 11.5 months and the 1-year probability of survival was 46.1%. The median event free survival (EFS) was 3.6 months (95% confidence interval, 2.5 to 4.8 months). Ten patients (25%) remain alive without evidence of disease. The median OS of 11 patients with CR at ASCT was not reached; of these, 7 patients (63.6%) were alive with CR. In multivariate analysis, CR at ASCT was a prognostic factor for EFS (P = 0.025) and OS (P = 0.027) and normal lactate dehydrogenase (LDH) at ASCT was a prognostic factor for improved OS (P = 0.025). Chemosensitive patients with PTCL who achieved CR before ASCT seem to benefit from HDT and ASCT. Pretransplant values of LDH had potential to predict the survival.


Lymphoma T-cell Peripheral Autologous Transplantation 


  1. 1.
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma (1997) The Non-Hodgkin’s Lymphoma Classification Project. Blood 89:3909–3918Google Scholar
  2. 2.
    Armitage JO, Greer JP, Levine AM, Weisenburger DD, Formenti SC, Bast M, Conley S, Pierson J, Linder J, Cousar JB, Nathwani BN (1989) Peripheral T-cell lymphoma. Cancer 63:158–163PubMedCrossRefGoogle Scholar
  3. 3.
    Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, Park CH, Park K (2001) CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349–352PubMedCrossRefGoogle Scholar
  4. 4.
    Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, Gonzalez M, Ribera JM, Brunet S, Garcia-Conde J, Fernandez de Sevilla A, Bosch F, Montserrat E (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9:849–855PubMedCrossRefGoogle Scholar
  5. 5.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545PubMedCrossRefGoogle Scholar
  6. 6.
    Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P, Reyes F (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18:3025–3030PubMedGoogle Scholar
  7. 7.
    Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001) High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27:711–716PubMedCrossRefGoogle Scholar
  8. 8.
    Kahl C, Leithauser M, Wolff D, Steiner B, Hartung G, Casper J, Freund M (2002) Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol 81:646–650PubMedCrossRefGoogle Scholar
  9. 9.
    Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF (2001) Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19:3766–3770PubMedGoogle Scholar
  10. 10.
    Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287–1295PubMedCrossRefGoogle Scholar
  11. 11.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri S, Piris MA, Ralfkiaer E, Warnke RA (1994) A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392PubMedGoogle Scholar
  12. 12.
    Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. IARC, LyonGoogle Scholar
  13. 13.
    A predictive model for aggressive non-Hodgkin’s lymphoma (1993) The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 329:987–994CrossRefGoogle Scholar
  14. 14.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  15. 15.
    Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A, Carreras E, Leon A, Arranz R, Fernandez de Sevilla A, Zuazu J, Garcia-Larana J, Rifon J, Varela R, Gandarillas M, San Miguel J, Conde E (2003) High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL–TAMO experience. Ann Oncol 14:1768–1775PubMedCrossRefGoogle Scholar
  16. 16.
    Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, Sureda A, Zuazu J, Marin J, Arranz R, Carreras E, Leon A, De Sevilla AF, San Miguel JF, Conde E (2003) High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL–TAMO experience. Haematologica 88:1372–1377PubMedGoogle Scholar
  17. 17.
    Siu LL, Chan JK, Kwong YL (2002) Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 17:539–554PubMedGoogle Scholar
  18. 18.
    Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK (1998) Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70–77PubMedGoogle Scholar
  19. 19.
    Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, Ngan KC, Lau WH, Wong KH, Yiu HY, Cheng HC, Au KH, Chan JK (2003) Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 14:1673–1676PubMedCrossRefGoogle Scholar
  20. 20.
    Bang SM, Kim YK, Park YH, Sohn SK, Lee JJ, Cho EK, Ryoo BY, Chung IJ, Yoon SS, Kim HJ, Lee JH, Yoon HJ, Park S (2005) High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. Leuk Lymphoma 46:1599–1604PubMedCrossRefGoogle Scholar
  21. 21.
    Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533–1538PubMedCrossRefGoogle Scholar
  22. 22.
    Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479PubMedCrossRefGoogle Scholar
  23. 23.
    Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, Franssila K, Soderstrom KO, Leppa S, Elonen E, Remes K, Nousiainen T (2004) Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 33:405–410PubMedCrossRefGoogle Scholar
  24. 24.
    Deconinck E, Lamy T, Foussard C, Gaillard F, Delwail V, Colombat P, Casassus P, Lemevel A, Brion A, Milpied N (2000) Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 109:736–742PubMedCrossRefGoogle Scholar
  25. 25.
    Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921PubMedGoogle Scholar
  26. 26.
    Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93:2697–2706PubMedGoogle Scholar
  27. 27.
    Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172–2176PubMedCrossRefGoogle Scholar
  28. 28.
    Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B (2005) Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant 36:271–273PubMedCrossRefGoogle Scholar
  29. 29.
    Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R (2004) Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 100:342–349PubMedCrossRefGoogle Scholar
  30. 30.
    Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D (1994) The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12:2588–2593PubMedGoogle Scholar
  31. 31.
    Sallah S, Wan JY, Nguyen NP (2001) Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113:185–187PubMedCrossRefGoogle Scholar
  32. 32.
    Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, Pileri SA, Tura S (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351–1353PubMedCrossRefGoogle Scholar
  33. 33.
    Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy–refractory peripheral T-cell lymphomas. Blood 103:2920–2924PubMedCrossRefGoogle Scholar
  34. 34.
    Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, de The H, Hermine O, Bazarbachi A (2005) Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 24:419–430PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Min Kyoung Kim
    • 1
  • Shin Kim
    • 1
  • Sung Sook Lee
    • 1
  • Sun Jin Sym
    • 1
  • Dae Ho Lee
    • 1
  • Seongsoo Jang
    • 2
  • Chan Jeong Park
    • 2
  • Hyun Sook Chi
    • 2
  • Jooryung Huh
    • 3
  • Cheolwon Suh
    • 1
  1. 1.Department of Internal Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  2. 2.Department of Diagnostic Laboratory Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  3. 3.Department of Pathology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea

Personalised recommendations